QUT ePrints (Queensland University of Technology) · 1997 · 29 citations · 0 references
MedicineGeneticsOncologyCancer GeneticsMolecular OncologyMolecular PathologyCancer Molecular PathologyGermline Cancer PredispositionGermline Cancer SusceptibilityHereditary Cancer SyndromesMalignant NeoplasmsOncogene MutationsCell Cycle InhibitionCell Cycle InhibitorsFamilial Cancer SyndromesGenetic Predisposition To CancerGermline Cancer Predisposition SyndromesGermline MutationsHereditary MelanomaSomatic Mutations
CDKN2A, the gene encoding the cell-cycle inhibitor p16CDKN2A, was first identified in 1994. Since then, somatic mutations have been observed in many cancers and germline alterations have been found in kindreds with familial atypical multiple mole/melanoma (FAMMM), also known as atypical mole syndrome. In this review we tabulate the known mutations in this gene and discuss specific aspects, particularly with respect to germline mutations and cancer predisposition.